Myeloma Clinical Trial
Official title:
Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)
The study is looking at how myeloma is related to low oxygen levels (hypoxia) in the bone marrow. This is to understand the disease better. It might also guide treatment in the future. For the study, we will run tests on a portion of the samples taken during a bone marrow biopsy. A bone marrow biopsy is taken as part of the diagnosis or follow up of myeloma. The tests in our study will look closely at the make-up of immune cells in the bone marrow, highlight areas of low oxygen, and look at genetic changes in cells from low-oxygen areas. We will ask patients to take a capsule the day before their bone marrow biopsy containing pimonidazole hydrochloride, a substance which will show up areas of low oxygen on tests. Overall we want to know: 1. If myeloma cells 'live' in areas of low oxygen in the bone marrow 2. What are the immune and bone marrow cells which are neighbours of myeloma cells? 3. Are there genetic changes in low oxygen myeloma cells For the pilot study, we want to know: 4. Can we use new techniques to study questions 1-3? The techniques we want to use are pimonidazole with multiplex immunohistochemistry and single cell RNA sequencing. The information we get from the tests will help us get a better understanding of how myeloma works. Future studies may also use these results to develop new kinds of drugs for myeloma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03832127 -
Evaluation of PET 18F-Fludarabine for the Initial Assessment and End-treatment of Symptomatic Multiple Myeloma Patients
|
Phase 1 | |
| Completed |
NCT01413178 -
A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
|
Phase 3 | |
| Recruiting |
NCT03641456 -
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
|
Phase 2 | |
| Completed |
NCT03135925 -
Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation
|
N/A | |
| Terminated |
NCT02907073 -
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT02114502 -
Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
|
Phase 2 | |
| Completed |
NCT01700608 -
Prospective Observational Study on Plerixafor After Chemotherapy
|
N/A | |
| Completed |
NCT00800839 -
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
|
Phase 2 | |
| Completed |
NCT00794261 -
Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma
|
Phase 2 | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Recruiting |
NCT05528887 -
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
|
Phase 1 | |
| Recruiting |
NCT05625971 -
Non-invasive MRD Assessment in Multiple Myeloma
|
||
| Active, not recruiting |
NCT02931942 -
Changing Over Time of Ascorbic Acid After Chemotherapy
|
||
| Active, not recruiting |
NCT05889221 -
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
|
N/A | |
| Recruiting |
NCT03836690 -
Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Active, not recruiting |
NCT02542657 -
Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma
|
Phase 1/Phase 2 | |
| Completed |
NCT01191060 -
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
|
Phase 3 | |
| Completed |
NCT01279694 -
Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)
|
Phase 1/Phase 2 | |
| Terminated |
NCT00983346 -
Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients
|
Phase 2 | |
| Completed |
NCT00476294 -
Long-Term Follow Up Study for AMD3100 Patients
|
N/A |